ASCO 2023 | Triple PD-1, LAG-3 and TIM-3 inhibition in solid tumors
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on results from a Phase I/II trial (NCT04370704) of retifanlimab, INCAGN02385, and INCAGN02390 in patients with advanced solid tumors. Combining anti-PD-1, LAG-3 and TIM-3 therapies was found to benefit patients, where the regimen was well tolerated in pretreated patients, and no novel toxicities were reported. Further research will assess this combination in the first-line setting in patients with treatment-naïve melanoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
